Durvalumab for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Preliminary results from a single-arm, phase 2 study

被引：0
|
作者：
Zandberg, D. [1 ]
Algazi, A. [2 ]
Jimeno, A. [3 ,4 ,5 ]
Good, J. S. [6 ]
Fayette, J. [7 ]
Bouganim, N. [8 ]
Ready, N. [9 ]
Clement, P. M. [10 ]
Goswmi, T. [11 ]
Jarkowski, A. [11 ]
Armstrong, J. M. [11 ]
Asubonteng, K. [11 ]
Melillo, G. [11 ]
Mesia, R. [12 ]
机构：
[1] Univ Maryland, Greenebaum Comprehens Canc Ctr, Hematol Oncol, Baltimore, MD 21201 USA
[2] Univ Calif San Francisco, Oncol, San Francisco, CA 94143 USA
[3] Univ Colorado, Canc Ctr, Dept Med Oncol, Colorado City, CO USA
[4] Univ Colorado, Canc Ctr, Dept Otolaryngol, Colorado City, CO USA
[5] Gates Ctr Regenerat Med, Colorado City, CO USA
[6] Queen Elizabeth Hosp, Inst Head & Neck Studies & Educ, Oncol, Birmingham, W Midlands, England
[7] Univ Lyon, Canc Ctr Ctr Leon Berard, Clin Oncol, Lyon, France
[8] McGill Univ, Hlth Ctr, Dept Oncol, Montreal, PQ, Canada
[9] Duke Univ, Med Ctr, Med Oncol, Durham, NC USA
[10] Univ Hosp Leuven, Dept Oncol, Leuven, Belgium
[11] AstraZeneca, Immunooncol GMD, Gaithersburg, MD USA
[12] Univ Barcelona, Catalan Inst Oncol, Med Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042O
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase 2 Trial of AT-101 in Combination With Docetaxel for Recurrent, Locally Advanced, or Metastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC) Management of Recurrent Head-and-Neck Squamous Cell Carcinoma
    Sacco, A.
    Nor, J.
    Belile, E.
    Sukari, A.
    Chepeha, D.
    Bradford, C.
    Eisbruch, A.
    Wolf, G.
    Urba, S.
    Worden, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 507 - 507
  • [32] Analysis of immune and genomic landscapes of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with pembrolizumab in the INSPIRE study
    Bernal, M. Oliva
    Lien, S.
    Wang, B. X.
    Yang, S. C.
    Spreafico, A.
    Jang, R.
    Elston, S.
    Jennings, S.
    Jiang, H.
    Haibe-Kains, B.
    Pugh, T.
    Ohashi, P.
    Siu, L. L.
    Hansen, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase 2 Clinical Trial
    Gold, Kathryn A.
    Kies, Merrill S.
    William, William N., Jr.
    Johnson, Faye M.
    Lee, J. Jack
    Glisson, Bonnie S.
    CANCER, 2018, 124 (10) : 2169 - 2173
  • [34] A phase I study of avelumab, palbociclib, and cetuximab (APC) in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC).
    Gold, Kathryn A.
    Sacco, Assuntina
    Bykowski, Julie
    Daniels, Gregory
    Pittman, Emily
    Messer, Karen
    Chen, Ruifeng
    Cohen, Ezra
    CANCER RESEARCH, 2021, 81 (13)
  • [35] Phase II Study of Saracatinib (AZD0530) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
    Fury, Matthew G.
    Baxi, Shrujal
    Shen, Ronglai
    Kelly, Katherine W.
    Lipson, Brynna L.
    Carlson, Diane
    Stambuk, Hilda
    Haque, Sofia
    Pfister, David G.
    ANTICANCER RESEARCH, 2011, 31 (01) : 249 - 253
  • [36] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
    Kim, E. S.
    Kies, M. S.
    Glisson, B. S.
    Ginsberg, L. E.
    Holsinger, F. C.
    Burke, B. J.
    Truong, M.
    Tsao, A. S.
    Hong, W. K.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
  • [37] Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Park, Robin
    Li, Jiannong
    Slebos, Robbert J. C.
    Chaudhary, Ritu
    Poole, Maria I.
    Ferraris, Carina
    Farinhas, Joaquim
    Hernandez-Prera, Juan
    Kirtane, Kedar
    Teer, Jamie K.
    Song, Xiaofei
    Hall, MacLean S.
    Tasoulas, Jason
    Amelio, Antonio L.
    Chung, Christine H.
    ORAL ONCOLOGY, 2024, 154
  • [38] Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial
    Adkins, Douglas
    Oppelt, Peter John
    Ley, Jessica C.
    Myneni, Praveen Chowdary
    Gogula, Venkata Ramana
    Kanumuri, Satish
    Yadla, Sheshubabu
    Sadu, Venkata
    Kota, Raghava
    Sanagala, Saipavan
    Surapaneni, Mounika
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Fury, Matthew G.
    Sherman, Eric
    Ho, Alan
    Katabi, Nora
    Sima, Camelia
    Kelly, Katherine W.
    Nwankwo, Oby
    Haque, Sofia
    Pfister, David G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 121 - 128
  • [40] Systemic treatment (ST) for untreated recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC): a comprehensive review of randomized phase III data
    Tukanova, Karina
    van Gogh, Evelien
    Govarts, Anouk
    Roets, Evelyne
    Specenier, Pol
    ACTA CLINICA BELGICA, 2017, 72 : 12 - 13
12345